Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTI-1090 in Advanced Solid Tumors
NCT03208959Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Aug 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HTI-1090 in solid tumor (5 arms), sponsored by Atridia Pty Ltd. Primary endpoints: Adverse events, Laboratory results and 2 more. Started Aug 2017; status: completed.
02
Drugs
HTI-1090
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03208959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208959.